The goal of the Biostatistics and Bioinformatics Core (Core B) is to address the statistical design and analysis needs of the Yale SPORE in Lung Cancer (YSILC) Projects, the other Cores, the Developmental Research Program (DRP), and the Career Development Program (CDP). To accomplish this goal we have assembled a highly interactive team of cancer biostatisticians and bioinformaticians who will work collaboratively with basic, clinical, translational, and population science researchers to advance the frontiers of cancer medicine.
The specific aims of the Biostatistics and Bioinformatics Core are:
Aim 1 : Provide collaboration and consulting in the design and analysis of basic, translational, population and clinical studies for YSILC;
Aim 2 : Oversee data management and ensure that data collected on all YSILC studies are of high quality and evaluated with statistical rigor;
and Aim 3 : Design and monitor the statistical conduct of clinical trials, ensuring data are collected and evaluated with statistical rigor and innovation.
For Aim1 the Core will address the analytic and informatics questions arising from the SPORE projects. Services provided by the Core will range from planning activities to consulting on specific analytic questions. More specifically, the Core will schedule regular meetings with the YSILC investigators, and maintain an open door policy for any biostatistical and bioinformatics questions.
For Aim 2 the Core will work closely with the investigators to analyze clinical trial data, next generation sequencing data, and bioinformatics data mining.
For Aim 3 the Core will design and monitor the statistical aspects of clinical trials for safety, efficacy and futility. Since the observed data can have characteristics different from what was hypothesized, the Core will conduct regular interim analyses, dynamically update the power calculations, develop new statistical and bioinformatics methodology as needed, provide timely suggestions to YSILC investigators, and thus play an important role in the projects in the YSILC. Biostatistics and Bioinformatics is also a key partner in the YSILC with representation on their Senior Leadership Team and participation in all core meetings.

Public Health Relevance

Well-designed, executed, and analyzed studies are critical to advancing the treatment and care of patients with lung cancer. Biostatistics and bioinformatics both have a critical role in the design, analysis, and interpretation of data from these studies that help to inform treatment and prevention strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-04
Application #
9529579
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Burslem, George M; Smith, Blake E; Lai, Ashton C et al. (2018) The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chem Biol 25:67-77.e3
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Choe, Junho; Lin, Shuibin; Zhang, Wencai et al. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556-560
Bade, Brett C; Hyer, J Madison; Bevill, Benjamin T et al. (2018) A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Integr Cancer Ther 17:921-927
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Bondeson, Daniel P; Smith, Blake E; Burslem, George M et al. (2018) Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 25:78-87.e5
O'Malley, Stephanie S; Zweben, Allen; Fucito, Lisa M et al. (2018) Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 75:129-138

Showing the most recent 10 out of 74 publications